[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100481733":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":47,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":24,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Ruijin Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"experimental group","EXPERIMENTAL","chemo-immunotherapy followed by thoracic radiotherapy and PD-1\u002FPD-L1 maintenance therapy",[13],"Radiation: thoracic radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","thoracic radiotherapy","Four courses of carboplatin\u002Fetoposide\u002Fanti-PD-1\u002FPD-L1 every 3 weeks All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after 6 cycle of platinum-based chemotherapy in combination with an anti-PD-1\u002FL1. Then, thoracic radiotherapy of 45 Gy\u002F15 fractions. PD-1\u002FPD-L1 maintenance therapy concurrently and after thoracic radiotherapy at least more than 6 months, or until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.",[9],null,[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Ruijin Hospital, Shanghai jiaotong univestigy school of medicine","RECRUITING","Shanghai","Shanghai Municipality","200025","China","CN",{"type":31,"coordinates":32},"Point",[33,34],121.45806,31.22222,{"lat":34,"lon":33},[37,42,45],{"name":38,"role":39,"phone":40,"phoneExt":20,"email":41},"Yifeng Wang","CONTACT","+862164370045","qwx12055@rjh.com.cn",{"name":43,"role":44,"phone":20,"phoneExt":20,"email":20},"Yi Xiang, Dr.","PRINCIPAL_INVESTIGATOR",{"name":46,"role":44,"phone":20,"phoneExt":20,"email":20},"Shengguang Zhao, Dr",{"type":44,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"QIWEIXIANG","Prof.","100481733","phase-ii-trial-of-consolidative-thoracic-radiotherapy-for-es-sclc-after-standard-care-of-chemo-immunotherapy-100481733",false,"NCT05552846","Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy","Consolidative Thoracic Radiotherapy for Extensive-stage Small-cell Lung Cancer Treated With Chemo-immunotherapy Followed by PD-1\u002FPD-L1 Maintenance Therapy：an Open Label, Single Arm Prospective Trial","Inclusion Criteria:\n\n1. Age between18 years and 80 years at time of study entry\n2. ECOG performance status of 0 or 1\n3. Body weight \\>30 kg\n4. Adequate bone marrow, liver and kidney function\n5. Life expectancy of at least 3 months\n6. At least one measurable (RECIST 1.1), thoracic lesion that can be irradiated with 45 Gy\u002F15 fractions\n7. Histologic or cytologic confirmation of small cell lung cancer\n8. Stage III-IV disease (TNM v8)\n9. Adequate pulmonary function with FEV1 \\>1 L or \\>30 % of predicted value and DLCO \\>30 % of predicted value\n10. Patients with brain metastases are eligible provided they are asymptomatic or treated and stable on steroids and\u002For anticonvulsants prior to the start of treatment -\n\nExclusion Criteria:\n\n1. Previous chemo-, immuno- or radiotherapy for SCLC\n2. Major surgical procedure last 28 days\n3. History of allogenic organ transplantation, autoimmune disease, immunodeficiency, hepatitis or HIV\n4. Uncontrolled intercurrent illness\n5. Other active malignancy\n6. Leptomeningeal carcinomatosis\n7. Immunosuppressive medication\n8. Pregnant or breastfeeding women","ALL","18 Years","80 Years",{"count":61,"type":62},104,"ESTIMATED","INTERVENTIONAL",[65],"NA","This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1\u002FPD-L1 plus etoposide platinum followed by PD-1\u002FPD-L1 maintenance therapy",[68],"Small-cell Lung Cancer",[70,71,72],"thoradic radiotherapy","immune checkpoint inhibitors","chemo-immunotherapy","2026-08-10",{"date":75,"type":76},"2026-08-12","ACTUAL",{"date":78,"type":76},"2021-01-30",{"date":80,"type":62},"2027-09-30",{"name":5,"class":6},1]